Betterlife Pharma INC. (BETRF) — SEC Filings

Q: What are the key financial highlights for Betterlife Pharma INC.?

Key financial highlights for Betterlife Pharma INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Betterlife Pharma INC.?

Key executives at Betterlife Pharma INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Betterlife Pharma INC. stock?

Risk factors for Betterlife Pharma INC. (BETRF) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Betterlife Pharma INC.?

Forward-looking statements and predictions from Betterlife Pharma INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Betterlife Pharma INC.. Recent 6-K filing on Apr 13, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Betterlife Pharma INC. on SEC EDGAR

Overview

Betterlife Pharma INC. (BETRF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 13, 2026: BetterLife Pharma Inc. filed a 6-K report on April 13, 2026, which includes several news releases from late 2025 and early 2026. These releases cover various company updates and material changes, indicating ongoing operational activities and disclosures.

Sentiment Summary

Across 25 filings, the sentiment breakdown is: 1 bearish, 24 neutral. The dominant filing sentiment for Betterlife Pharma INC. is neutral.

Filing Type Overview

Betterlife Pharma INC. (BETRF) has filed 23 6-K, 2 20-F with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (25)

BetterLife Pharma Files 6-K with Historical News Releases — 6-K · Apr 13, 2026 Risk: low
BetterLife Pharma Inc. filed a 6-K report on April 13, 2026, which includes several news releases from late 2025 and early 2026. These releases cover various co
BetterLife Pharma Inc. Files 6-K Report — 6-K · Sep 29, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on September 29, 2025, for the month of September 2025. The company, formerly known as Pivot Pharmaceuticals Inc. and Ne
BetterLife Pharma Inc. Files July 2025 6-K Report — 6-K · Jul 28, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on July 28, 2025, reporting for the month of July 2025. The company, formerly known as Pivot Pharmaceuticals Inc. and Ne
BetterLife Pharma Inc. Files June 2025 6-K Report — 6-K · Jun 27, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on June 27, 2025, for the month of June 2025. The company, formerly known as Pivot Pharmaceuticals Inc. and Neurokine Ph
BetterLife Pharma Inc. Files June 2025 6-K Report — 6-K · Jun 23, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on June 23, 2025, reporting for the month of June 2025. The company, formerly known as Pivot Pharmaceuticals Inc. and Ne
BetterLife Pharma's Net Loss Widens 23% Amid Zero Revenue — 20-F · Jun 2, 2025 Risk: high
BetterLife Pharma Inc. reported no revenue for the fiscal year ended January 31, 2025, consistent with its pre-revenue stage as a pharmaceutical company. The co
BetterLife Pharma Inc. Files May 2025 6-K Report — 6-K · May 30, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on May 30, 2025, for the month of May 2025. The company, formerly known as Pivot Pharmaceuticals Inc. and Neurokine Phar
BetterLife Pharma Files Routine 6-K Report — 6-K · May 7, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on May 7, 2025, reporting for the month of May 2025. The company, formerly known as Pivot Pharmaceuticals Inc. and Neuro
BetterLife Pharma Inc. Files Routine 6-K Report — 6-K · Apr 7, 2025 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on April 7, 2025, reporting for the month of April 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and N
BetterLife Pharma Files December 2024 6-K Report — 6-K · Dec 31, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K for the month of December 2024, reporting as a foreign private issuer. The company, formerly known as Pivot Pharmaceutic
BetterLife Pharma Inc. Files 6-K Report — 6-K · Dec 9, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on December 9, 2024, reporting for the month of December 2024. The company, formerly known as Pivot Pharmaceuticals Inc.
BetterLife Pharma Inc. Files October 2024 6-K Report — 6-K · Oct 15, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on October 15, 2024, reporting for the month of October 2024. The company, formerly known as Pivot Pharmaceuticals Inc.
BetterLife Pharma Files July 2024 6-K Report — 6-K · Sep 26, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K for the month of July 2024, reporting as a foreign private issuer. The company, formerly known as Pivot Pharmaceuticals
BetterLife Pharma Inc. Files August 2024 6-K Report — 6-K · Aug 29, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on August 29, 2024, reporting for the month of August 2024. The company, formerly known as Pivot Pharmaceuticals Inc. an
BetterLife Pharma Inc. Files July 2024 6-K Report — 6-K · Aug 8, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on August 8, 2024, for the month of July 2024. The company, previously known as Pivot Pharmaceuticals Inc. and Neurokine
BetterLife Pharma Inc. Files July 2024 6-K Report — 6-K · Jul 15, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on July 15, 2024, reporting for the month of July 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Ne
BetterLife Pharma Files April 2024 6-K Report — 6-K · Jun 28, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K for the month of April 2024, reporting on its activities as a foreign private issuer. The company, formerly known as Piv
BetterLife Pharma Inc. Files June 2024 6-K Report — 6-K · Jun 17, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on June 17, 2024, reporting for the month of June 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Ne
BetterLife Pharma Files 20-F for FY2024 — 20-F · May 30, 2024 Risk: medium
BetterLife Pharma Inc. filed its annual 20-F report for the fiscal year ending January 31, 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and N
BetterLife Pharma Files 6-K Report — 6-K · May 14, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on May 14, 2024, reporting for the month of May 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Neur
BetterLife Pharma Files 6-K Report — 6-K · May 6, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on May 6, 2024, reporting for the month of May 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Neuro
BetterLife Pharma Inc. Files Routine 6-K Report — 6-K · Apr 11, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on April 11, 2024, reporting for the month of April 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and
BetterLife Pharma Inc. Files April 2024 6-K Report — 6-K · Apr 4, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on April 4, 2024, reporting for the month of April 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and N
BetterLife Pharma Inc. Files March 2024 6-K Report — 6-K · Mar 5, 2024 Risk: low
BetterLife Pharma Inc. filed a Form 6-K on March 5, 2024, for the month of March 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Neurokine P
BetterLife Pharma Files 6-K, Attaches Material Change Report — 6-K · Jan 2, 2024
BetterLife Pharma Inc. filed a Form 6-K on January 2, 2024, for the month of December 2023, indicating it is a foreign private issuer. This filing primarily ser

Risk Profile

Risk Assessment: Of BETRF's 24 recent filings, 1 were flagged as high-risk, 1 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and stringent regulatory hurdles. Companies in this sector, especially those in the pre-revenue stage like BetterLife Pharma, must navigate complex clinical trials and approval processes. The focus on psychedelic and antiviral therapies indicates an alignment with emerging trends in drug development, though these areas also present unique regulatory and market challenges.

Top Tags

foreign-private-issuer (16) · 6-K (7) · regulatory-filing (7) · reporting (7) · sec-filing (6) · foreign-issuer (5) · company-update (4) · 6-k (3) · corporate-history (2) · routine-filing (2)

Key Numbers

Filing Date: 20250929 — Date the report was filed with the SEC.
Period of Report: 20250926 — The period this report covers.
Revenue: $0 — No revenue generated for fiscal year 2025, indicating pre-revenue stage.
Net Loss: $2.49M — Increased from $2.02M in FY2024, representing a 23.37% deterioration.
Increase in Net Loss: 23.37% — Year-over-year increase in net loss from FY2024 to FY2025.
Total Assets: 30140643 — Represents the company's total assets as of the fiscal year end.
Total Liabilities: 31259127 — Represents the company's total liabilities as of the fiscal year end.
Net Income: 2486803 — Indicates the company's profitability for the fiscal year.

Frequently Asked Questions

What are the latest SEC filings for Betterlife Pharma INC. (BETRF)?

Betterlife Pharma INC. has 25 recent SEC filings from Jan 2024 to Apr 2026, including 23 6-K, 2 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BETRF filings?

Across 25 filings, the sentiment breakdown is: 1 bearish, 24 neutral. The dominant sentiment is neutral.

Where can I find Betterlife Pharma INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Betterlife Pharma INC. (BETRF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Betterlife Pharma INC.?

Financial highlights for Betterlife Pharma INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for BETRF?

The investment thesis for BETRF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Betterlife Pharma INC.?

Executive information for Betterlife Pharma INC. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Betterlife Pharma INC. stock?

Of BETRF's 24 assessed filings, 1 were flagged high-risk, 1 medium-risk, and 22 low-risk.

What are recent predictions and forward guidance from Betterlife Pharma INC.?

Forward guidance and predictions for Betterlife Pharma INC. are extracted from SEC filings as they are enriched.